Daniel Brennan

Subbu Nambi

Subhalaxmi Nambi

Yuko Oku

Elizabeth Koslosky

Jason Lai

Matthew Stanton

Matthew Sykes

- Nautilus Biotechnology is developing a **disruptive iterative mapping platform** to address the inefficiencies in drug development by providing a new approach to protein measurement, with a market projected to reach **$57 billion by 2030**.  **[1808805_2145740_1]** **[1808805_2145740_4]** **[1808805_2145740_7]** 
- The company plans to launch its platform in **late 2026**, with the instrument priced at **$1 million** and consumables designed to generate **$1 million in pull-through over time**.  **[1808805_2145740_7]** 
- Nautilus reported **$180 million** in cash on its balance sheet in Q2, anticipating these funds will last through **2027**, and has reduced operating expenses by approximately **20% year-over-year**.  **[1808805_2145740_7]** 
- Founders maintain significant ownership, holding **32%** of the company, indicating strong alignment with shareholder interests.  **[1808805_2145740_8]**

Nautilus Biotechnology (NAUT)